Edition:
United States

People: Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

516.45INR
5:28am EST
Change (% chg)

Rs-0.60 (-0.12%)
Prev Close
Rs517.05
Open
Rs517.05
Day's High
Rs521.85
Day's Low
Rs514.50
Volume
199,557
Avg. Vol
483,111
52-wk High
Rs730.75
52-wk Low
Rs433.15

Subramanian, Kalyanasundaram 

Mr. Kalyanasundaram Subramanian serves as Whole Time Director of the Company. He joined Sun Pharmaceutical Industries Limited ('Sun') in January 2010 after 22 years with GSK in various parts of the world. Mr. Kal is a Chemistry graduate and a Chartered Accountant from India with 37 years of experience of which some 30 years in the pharmaceutical industry. Mr. Kat's career in Pharma industry began when he joined Burroughs Wellcome, in New Zealand as Commercial Advisor in 1988. His long and varied career with Burroughs Wellcome in New Zealand which was acquired by Glaxo to become GlaxoWellcome and finally GlaxoSmithKline, includes assignments as Vice President, head of Classic Brands business of Emerging Markets; Area Director South Asia & Managing Director, GSK India; Managing Director - GlaxoWellcome, Singapore (Singapore, Indochina & Myanmar). Commercial Director - Burroughs Wellcome, New Zealand. In 2010, Kal joined Sun as the CEO and Director to manage India and Emerging Markets. Kal was instrumental in Merck (MSD) and Sun collaboration and spearheaded opening of Sun operations in few important markets such as Japan, MENA. In 2012, Kal moved to USA to Taro Pharmaceutical Industries Ltd. ('Taro'), a subsidiary of Sun, to assume responsibility of Taro's operations in North America. In January 2017, Kal moved back to India to manage India and EM regions of Sun. On February 13, 2017, Kal has also been appointed as the CEO & Whole-time Director of Sun Pharma Laboratories Limited, a wholly owned subsidiary of Sun.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --